Tet Technology will be applied to Stemgent’s viral vector systems for iPS cells.

Stemgent entered into an agreement to market reagents based on TET Systems’ technology for creating inducible stem cells. Stemgent will apply Tet Technology to its portfolio of viral vector systems for induced pluripotent stem (iPS) cells.

Tet Technology is based on regulatory components of the E. coli tetracycline-resistance operon. Once established in the cell line, the inducer doxycycline, a tetracycline derivative, will control the system in a dose-dependent manner. This will allow researchers to precisely modulate the expression levels of target genes and other transcription factors identified as important in the generation of iPS cells, according to the firms.


To comment on this story, go to BLOGbiotech.

Previous articleAvexa Responds to Cytopia’s Statement Concerning Merger with Progen
Next articleFerring Opens San Diego Center for Peptide Research